Abstract CT129: ARC-3: Updated results of etrumadenant (AB928) + modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients
Cecchini M, Quah C, Liu S, Woloski R, Udyavar A, Giannakis M. Abstract CT129: ARC-3: Updated results of etrumadenant (AB928) + modified FOLFOX-6 (mFOLFOX-6) in metastatic colorectal cancer (mCRC) patients. Cancer Research 2021, 81: ct129-ct129. DOI: 10.1158/1538-7445.am2021-ct129.Peer-Reviewed Original ResearchModified FOLFOX-6Metastatic colorectal cancerFOLFOX-6American Association for Cancer Research annual meetingsColorectal cancerAnti-tumor immune responseAssociated with disease controlDying cancer cellsMCRC ptsAdenosine receptor blockadeOpen-label studyRelease of ATPAntagonists of A2ARMedian PFSPretreated ptsReceptor blockadeEligible ptsOrally onceExtracellular adenosineA2B receptorsImmune cellsChemotherapeutic agentsTherapeutic efficacyClinical activityImmune response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply